Rituximab: Pharmacology, clinical indications and health benefits

Rituximab: Pharmacology, Clinical Uses and Health Effects

Volumn , Issue , 2012, Pages 1-29

  Méndez, Miriam ^a   Provencio, Mariano ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84895287749     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (116)

1. Miller RA, Maloney DG, Warnke R et al. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N. Engl. J. Med. 1982;306:517-522.
2. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359-68.
3. Stockmeyer B, Dechant M, van Egmond M, et al. Triggering FC{alpha}-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. J. Immunol. 2000;165:5954-61.
4. Plosker GL, Figgitt DP. Rituximab: a review of its use in non Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003;63(8): 803-43.
5. Skvortsova I, Popper BA, Skvortsov S, et al. Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells. J. Radiat. Res. 2005;46(2): 241-8.
6. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol. 2001;19:2165-70.
7. Pfreundschuh M, Zeynalova S, Poeschel V, et al. Dose-dense rituximab improves outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL): results of the DENSE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). ASH Annual Meeting Abstracts, 2007;110:789.
8. Berinstein NL, Grillo-López AJ, White CA, et al. Association of serum rituximab concentrations and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol, 1998;9 (9): 995-1001.
9. Watier H. Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteins. Expert Opin. Biol. Ther. 2005;5 (Suppl. 1): S29-36.
10. Ghielmini M, Rufibach K, Salles G, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann. Oncol. 2005;16: 1675-82.
11. Mc Laughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol, 1998;16 (8): 2825-33.
12. Wierda WG, Ketaing MJ, O'Brien S. Refractory chronic lymphocytic leukemia: prognosis and treatment options. American Journal of Cancer 2004;3 (3): 163-78.
13. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J. Clin. Oncol. 2008;26(28):4579-4586.
14. Herold M, Haas A, Srocket S, al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J. Clin. Oncol. 2007;25(15):1986-1992.
15. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106(12):3725-3732.
16. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL 2000 study. Blood 2008;112(13):4824-4831.
17. Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis. J. Natl. Cancer Inst. 2007;99(9):706-714.
18. Forstpointner R, Dreyling M, Repp R, et al. 2004. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064-71.
19. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non- Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 2006;108(10):3295-3301.
20. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J. Clin. Oncol. 2005;23: 3383-9.
21. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J. Clin. Oncol. 2008;26: 4473-9.
22. Weide R, Hess G, Koppler H, et al. High anti-lymphoma activity of bendamustine/mitoxantrone/ rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk. Lymphoma. 2007;48: 1299-306.
23. Rummel M, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent and mantle cell lymphomas-final results of the randomized phase III study NHL 2-2003 on behalf of the StiL (Study Group Indolent Lymphomas, Germany). Blood. 2010;116:Abstract 856.
24. Rummel M, Niederle N, Maschmeyer G. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular indolent and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood. 2009;114:Abstract 405.
25. Rummel MJ, Gregory SA. Bendamustine's emerging role in the management of lymphoid malignancies. Semin. Hematol. 2011 Apr;48 Suppl 1:S24-36.
26. Ghielmini M, Schmitz SFH, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly ×4 schedule. Blood 2004;103(12):4416-4423.
27. Hainsworth JD, Litchy S, Shaffer DW, et al. Maximizing therapeutic benefit of rituximab: Maintenance therapy versus retreatment at progression in patients with indolent non-Hodgkin's lymphoma. A randomized phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 2005;23(6):1088-1095.
28. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG 1496 Study. J. Clin. Oncol. 2009;27(10):1607-1614.
29. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group (GLSG). Blood 2006;108(13):4003-4008.
30. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011 Jan;377(9759): 42-51.
31. Williams ME. ECOG 4402: Randomized phase III trial comparing two different rituximab dosing regimens for patients with low tumor burden indolent non-Hodgkin's lymphoma. Curr. Hematol. Rep. 2004;3(6):395-396.
32. McKelvey E, Gottlieb J, Wilson H et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer (1976);38:1484-1493.
33. Fisher R, Gaynor E and Dahlberg S et al., Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma, N. Engl. J. Med. (1993);328:1002-1006.
34. Gordon L, Harrington D, Andersen J, et al.: Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N. Engl. J. Med. (1992);327 (19): 1342-9.
35. Cooper I, Wolf M, Robertson T et al. and The Australian and New Zealand Lymphoma Group, Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma, J. Clin. Oncol. (1994);12: 769-778.
36. Sonneveld P, de Ridder M, van der Lelie H, Nieuwenhuis K, Schouten H, Mulder A, van Reijswoud I, Hop W, Lowenberg B. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J. Clin. Oncol. (1995);13:2530-2539.
37. Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 2001;19(2):389-397.
38. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H and Bouabdallah R et al., CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma, New Engl. J. Med. 2002;4:235-242.
39. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R and FerméC et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. J. Clin. Oncol. 2005;18: 4117-4126.
40. Coiffier B, Feugier P, Mounier N, et al. Long-term results of the GELA study comparing RCHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients [abstract]. Proc. ASCO. (2007);25:443a.
41. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP(R-CHOP) in the treatment of elderly patients with diffuse large B-cell lymphoma (DLBCL) overcomes bcl2-associated chemotherapy resistance (Abstract). Blood 2002;100(Suppl 1):161a, 603.
42. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J. Clin. Oncol. 2006;24(19):3121-3127.
43. Pfreundschuh M, Kloess M, Zeynalova S, et al. German High-Grade Non-Hodgkin Lymphoma Study Group. Six vs. Eight cycles of bi-weekly CHOP-14 with or without Rituximab for elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the completed RICOVER-60 trial of the German High-Grade non-Hodgkin Lymphoma Study Group (DSHNHL) [abstract], Blood 108 2006 (11) [Abstract #205].
44. Pfreundschuh M, Trümper L, Österborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet. Oncol. 2006;7(5):379- 391.
45. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J. Clin. Oncol. 2005;23(22):5027-5033.
46. Kaplan L, Lee J, Ambinder R, Sparano J, Cesarman E and Chadburn A et al., Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010, Blood 2005;106: 1538-1543.
47. Sonneveld P, Wim van Putten, Douwe Biesma, Harald Holte, Marinus van Marwijk Kooij, Mark Henri H. Kramer, P.W. Wijermans, Monique Steijaert, Gustaaf W. van Imhoff, P.J. Lugtenburg, P.C. Huijgens, and Mikael Eriksson Phase III Trial of 2-Weekly CHOP with Rituximab for Aggressive B-Cell Non-Hodgkin's Lymphoma in Elderly Patients. Blood ASH Meeting Abstract 2006;108:210.
48. Delarue, R, Tilly, H, Salles, G, et al. R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B cell lymphoma: results of the interim analysis of the LNH03-6B GELA study (abstract 406). Blood 2009;114:169.
49. Rueda A, Sabin P, RifáJ, Llanos M, Gómez-Codina J, Lobo F, García R, Herrero J, Provencio M, Jara C. R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study. Hematol. Oncol. 2008, 26(1):27-32.
50. Brusamolino E, Rusconi C, Montalbetti L, Gargantini L, Uziel L, Pinotti G, Fava S, Rigacci L, Pagnucco G, Pascutto C, Morra E, Lazzarino M. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse largeB-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006;91(4):496-502.
51. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood (2004)15;103(10):3684-8.
52. Witzig TE, Geyer SM, Kurtin PJ, et al. Salvage chemotherapy with rituximab DHAP (RDHAP) for relapsed non-Hodgkin lymphoma (NHL): a phase II trial of the North Central Cancer Treatment Group (NCCTG) [abstract]. ProcASCO (2006);24:440s.
53. Kim MK, Kim S, Lee SS, Sym SJ, Lee DH, Kim SW, Jang S, Park CJ, Chi HS, Huh J, Suh C. Rituximab-ESHAP as a mobilization regimen for relapsed or refractory B-cell lymphomas: a comparison with ESHAP. Transfusion (2007);47(8):1447-54.
54. Jermann M, Jost LM, Taverna Ch, Jacky E, Honegger HP, Betticher DC, Egli F, Kroner T, Stahel RA. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann. Oncol. 2004;15(3):511-6.
55. Glass B, Kloess M, Engert A, et al. Dose escalated CHOP + etoposide and repetitive autologous stem cell transplantation (MegaCHOEP) with and without rituximab for primary treatment of aggressive NHL. J. Clin. Oncol. (2005);23:Abstract 6654.
56. Gisselbrecht C, Glass B, Mounie N. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study (Abstract 8509). Clin. Oncol. 2009 (Suppl);27:15s.
57. Vacirca JL, Acs PI, Shimkus BJ, Rosen PJ. Bendamustine/ rituximab in relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol. 2010;28(15s):Abstract 8041.
58. Habermann T, Weller E, Morrison V et al., Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma, J. Clin. Oncol. 2006;24: 3121-3127.
59. Almasri NM, Duque RE, Iturraspe J et al. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am. J. Hematol. 1992;40:259-263.
60. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 1998, 16:2825-33.
61. Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001;98:1326-31.
62. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol. 2001;19:2165-70.
63. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. 2001;19:2153-64.
64. Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as fi rst-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 2003;21:1746-51.
65. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fl udarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975-80.
66. Hallek M, Fingerle-Rowson G, Fink AM, et al. Fist line treatment with fludarabine (F), cyclophosphamide (c), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group (abstract no. 535) Blood (ASH Annual Meeting Abstracts) 2009;114.
67. Robak T, Lech-Maranda E, Robak P. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia. Expert Rev. Anticancer. Ther. 2010 Oct;10(10):1529-43.
68. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fl udarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J. Clin. Oncol. 2005;23:4070-8.
69. Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J. Clin. Oncol. 2010;28(10):1756-65. Epub 2010 Mar 1.
70. Ghielmini M, Rufibach K, Salles G, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann. Oncol. 2005;16: 1675-82.
71. Romaguera JE, Fayad LE, Feng L, et al. Ten year follow-up after intense chemoimnunotherapy with rituximab-HyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggresssive mantle cell lymphoma. Br. J. Haematol. 2010;150(2): 200-8.
72. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J. Clin. Oncol. 2005;23:1984-92.
73. Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann. Oncol. 2009;20:520-5.
74. Lamm W, Kaufmann H, Raderer M, et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica 2011 96(7):1008-14. Epub 2011 Apr 12.
75. Wang M, Han XH, Zhang L, Yang J, Qian JF, Si YK et al. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia. 2008;22(1):179-85.
76. Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib and rituxiamb for patients with relapsed/refractoy indolent and mantle cell non-Hodgkin lymphoma. Blood 2011;117(19): 2807-12.
77. Maloney D, Liles T, Czerwinski D et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8 in patients with recurrent B-cell lymphoma. Blood 1994;84: 2457- 2466.
78. Hauptrock B, Hess G. Rituximab in the treatment of non-Hodgkin's lymphoma. Biologics: Targets and Therapy 2008:2(4) 619-633.
79. Aurran-Schleinitz T, Gravis G, Vittot M, et al: One hour rituximab infusion is safe and improves patient care and outpatient unit management. Blood 106, 2005 (abstr 4759).
80. Provencio M, Cerdeira S, Bonilla F, et al: Rapid-infusion rituximab in lymphoma treatment. Ann. Oncol. 17:1027-1028, 2006.
81. Middleton H, Mollee P, Bird R, et al: Accelerated delivery of rituximab is safe on an out-patient basis. Blood 106, 2005 (abstr 4777).
82. Salar A, Casao D, Cervera M, et al: Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution. Eur. J. Haematol. 77:338-340, 2006.
83. Milone J, Prates V, Zoppegno L, et al: Rapid infusion of rituximab (RIR) is well tolerated and can safely be delivered in patients with lymphoproliferative diseases. Blood 110, 2007 (abstr 4503).
84. Atmar J. Review of the safety and feasibility of rapid infusion of rituximab. J. Oncol. Pract. 2010;6(2):91-3.
85. Siano M, Lerch E, Zucca E, et al: A phase I-II study to determine the maximum tolerated infusion-rate of rituximab, with a special emphasis on monitoring the effect of rituximab on cardiac function. Clin. Cancer Res. 2008;14:7935-7939.
86. Tuthill M, Crook T, Corbet T, et al: Rapid infusion of rituximab over 60 min. Eur. J. Haematol. 2009;82:322-325.
87. Corey P, Go R, Schaper A: A nurse can safely deliver rituximab over 90 minutes. Oncology Nursing Society 32nd Annual Congress. April 24-27, 2007, Las Vegas, NV (abstr 2010).
88. Gibbs S, Pout G, Wimperis J: Rapid infusion rituximab is as clinically effective and safe as conventional infusion regimes in the treatment of diffuse large B-cell lymphoma: A 2-year prospective study. Haematologica 92, 2007 (suppl 2;abstr 0708).
89. Al Zahrani A, Ibrahim N, Al Eid A. Rapid infusion rituximab changing practice for patient care. J. Oncol. Pharm. Pract. 15:183-186, 2009.
90. Sehn LH, Donaldson J, Filewich A, et al: Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood 109: 4171-4173, 2007.
91. Edwards J, Leandro M, Cambridge G. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum. Dis. Clin. North Am. (2004);30: 393- 403.
92. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat. Rev. (2005);31(6):456-73.
93. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005, 106:1538-1543.
94. Spina M, Jaeger U, Sparano JA, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood 2005, 105:1891-1897.
95. Biogen Idec Inc., Genentech Inc. Rituxan (Rituximab): prescribing information. 2006 Feb 28.
96. Vallet S, Tempescul A, Tran A, et al. Cytomegalovirus-associated meningoradiculoneuritis after treatment of mantle cell lymphoma with a combination of chemotherapy and rituximab. Ann. Hematol. 2005, 84:545-547.
97. Precupanu CM, Girodet J, Mariani P, et al. Pseudo-bowel obstruction due to varicella zoster virus infection after autologous stem cell transplantation. Am. J. Hematol. 2009, 84:127-128.
98. Quartier P, Tournilhac O, Archimbaud C, et al. Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment. Clin. Infect. Dis. 2003, 36:e47-49.
99. Matteucci P, Magni M, Di Nicola M,et al. Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood 2002, 100:1104-1105.
100. Ennishi D, Terui Y, Yokoyama M, et al. Increased incidence of interstitial pneumonia by CHOP combined with rituximab. Int. J. Hematol. 2008, 87:393-397.
101. Lanini S, Molloy AC, Fine PE, et al. Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Med. 2011 Apr 12;9:36.
102. Tsutsumi Y, Kanamori H, Mori A et al. Reactivation of hepatitis B virus with rituximab. Expert Opin. Drug Saf. 2005;4: 599- 608.
103. Tsutsmi Y, Ogasawara R, Kamihara Y. Rituximab administration and reactivation of HBV. Hepal. Res. Treat. 2010: 182067. Epub 2010 Dec 1.
104. Roccatello D, Baldovino S, Rossi D et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol. Dial. Transplant. 2004;19: 3054- 3061.
105. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113(20):4834-4840.
106. Vaughn C, Zhang L, Schiff D. Reversible posterior leuko-encephalopathy syndrome in cancer. Curr. Oncol. Rep. 2008;10(1):86-91.
107. Johnston KM, Marra CA, Connors JM, et al. Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada. Value Health. 2010;13(6):703-11.
108. Hamblin T, Best JH, Hornberger J, et al. Cost-effectiveness of rituximab in treatment of diffuse large B-cell lymphoma (abstract no. 170). Br. J. Haematol. 2002;74(3): 194-202.
109. Hornberger J, Best J. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer 2005;103(8):1644-51.
110. Groot M, Lugtenburg P, Hornberger J, Huijgens P, Uyl-de Groot C. Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands. Eur. J. Haematol. 2005;74(3):194-202.
111. Cvetkovic RS, Perry CM. Rituximab: a review of its use in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. Drugs 2006;66(6): 791-820.
112. Casado F, García Marco JA, Gilsanz F, et al. Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia. Gac. Sanit. 2011 Jun 9. [Epub ahead of print].
113. Herold M, Pasold R, Srock S, et al. Results of a prospective randomised oopen label phase III study comparing rituximab plus mitoxantrone, chlorambucile , prednisolone chemotherapy (R-MCP) versus MCP alone in untreated indolent non-Hodgkin's lymphoma (NHL) and mantle-cell-lymphoma (MCL). Blood 2004;104(11): 169.
114. Hieke K, Pasold R, Neser S, et al. Cost evaluation of rituximab plus MCP vs MCP alone in advanced stage indolent non-Hodgkin's lymphoma based on a randomized controlled multicenter trial (abstract no.87) Blood 2004;104 (11): 28-9.
115. Soini EJ, Martikainen JA, Nousiainen T, et al. Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up. Ann. Oncol. 2011;22(5):1189-97.
116. Dotan E, Aggarwal C, Smith MR. Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma. P and T. 2010;35(3):148-57.